- Global Pharma News & Resources

Arcus Biosciences Presents Data from its Pipeline at Multiple Scientific Conferences

  • Initial pharmacokinetic (PK)/pharmacodynamic (PD) data for AB521, Arcus’s HIF-2a inhibitor, in healthy volunteers confirm its potential to have an improved clinical profile compared to that of the only approved HIF-2a inhibitor; data were presented at ESMO Targeted Anticancer Therapies Congress, March 7-8, 2022.
  • PK/PD modeling for etrumadenant, quemliclustat and zimberelimab will be presented at the American Society for Clinical Pharmacology & Therapeutics (ASCPT), March 16-18, 2022.
  • Preclinical research related to therapeutic opportunities to enhance anti-tumor immunity and new insights into the benefit of dual A2a/A2b adenosine receptor antagonism, CD39 inhibition and HPK1 inhibition will be presented at the American Association for Cancer Research, April 8-13, 2022.

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced several poster presentations at upcoming scientific conferences that support the ongoing investigation of its clinical and preclinical pipeline.

“Scientific exchange fosters progress in research, and we value the opportunity to contribute to the advancement of cancer research by presenting early data that support the clinical approach to investigating our molecules,” said Terry Rosen, Ph.D., Chief Executive Officer of Arcus. “The AB521 data presented at the ESMO TAT Congress confirm its potential to have an improved clinical profile compared to that of the approved HIF-2a inhibitor; we plan to advance this molecule into a Phase 1/1b study in patients with clear-cell renal cell carcinoma in mid-2022. Etrumadenant, quemliclustat and zimberelimab are already being investigated in randomized and late-stage studies across common cancers like colon, lung, pancreas and prostate.”

ESMO Targeted Anticancer Therapies Congress, March 7-8, 2022

Title: AB521, a Clinical-Stage, Potent, and Selective Hypoxia-Inducible Factor (HIF)-2α Inhibitor, for the Treatment of Renal Cell Carcinoma
Abstract number: 252

American Society for Clinical Pharmacology & Therapeutics (ASCPT), March 16-18, 2022

Title: A Mechanistic Pharmacokinetic-Pharmacodynamic (PK-PD) Model of Quemliclustat (AB680), a Small-Molecule Inhibitor of CD73, in Healthy Volunteers and Patients with Gastrointestinal Malignancies
Abstract number: P-102

Title: Population Pharmacokinetics and Pharmacodynamics of Etrumadenant (AB928) in Healthy Volunteers and Cancer Patients
Abstract number: P-196

Title: Population Pharmacokinetics of Zimberelimab (AB122) and Dose Justification by Model Informed Drug Development (MIDD) Approach
Abstract number: P-032

American Association for Cancer Research, April 8-13, 2022

Title: Inhibition of CD39 Results in Elevated ATP and Activation of Myeloid Cells to Promote Anti-Tumor Immunity
Abstract number: 4151

Title: Dual A2aR/A2bR Antagonism with Etrumadenant (AB928) Eliminates the Suppressive Effects of Adenosine on Immune and Cancer Cells in the Tumor Microenvironment
Abstract number: 2728

Title: HPK1 Inhibition Enhances T Cell Activation and Relieves the Immunosuppressive Phenotype of Inhibitory Signals Found in the Tumor Microenvironment
Abstract number: 5762

Arcus Clinical Study Overview






Lung Cancer


zim vs. zim + dom vs. zim +
dom + etruma

1L NSCLC (PD-L1 ≥ 50%)

Phase 2



durva ± dom

Curative-Intent Stage 3 NSCLC

Phase 3



chemo vs. zim vs. zim + dom

1L NSCLC (PD-L1 ≥ 50%)

Phase 3


Colon Cancer


etruma + zim + mFOLFOX vs.

2L/3L/3L+ CRC

Phase 2


Pancreatic Cancer


quemli + zim + gem/nab-pac
vs. quemli + gem/nab-pac


Phase 1/1b


Prostate Cancer


etruma + zim + SOC vs. SOC


Phase 2




AB308 + zim

Advanced Malignancies

Phase 1/1b




Healthy Volunteer

Phase 1


Carbo/pem: carboplatin/pemetrexed; dom: domvanalimab; durva: durvalumab; etruma: etrumadenant; gem/nab-pac: gemcitabine/nab-paclitaxel; quemli: quemliclustat; R/R: relapsed/refractory; SOC: standard of care; zim: zimberelimab CRC: colorectal cancer; CRPC: castrate-resistant prostate cancer; NSCLC: non-small cell lung cancer; PDAC: pancreatic ductal adenocarcinoma

About Arcus Biosciences

Arcus Biosciences is a clinical-stage, global biopharmaceutical company developing differentiated molecules and combination medicines for people with cancer. In partnership with industry partners, patients and physicians around the world, Arcus is expediting the development of first- or best-in-class medicines against well characterized biology and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has expedited the development of six investigational medicines into clinical studies, including new combination approaches that target TIGIT, PD-1, the adenosine axis (CD73 and dual A2a/A2b receptor) and most recently, HIF-2a. For more information about Arcus Biosciences’ clinical and pre-clinical programs, please visit or follow us on Twitter.

Forward-Looking Statements

This press release contains forward-looking statements. All statements regarding events or results to occur in the future contained herein, including, but not limited to, the potential for AB521 to have an improved clinical profile, and the advancement and associated timing of the Phase 1/1b study in patients, are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements involve known and unknown risks and uncertainties and other important factors that may cause Arcus’s actual results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: risks associated with preliminary and interim data; the unexpected emergence of adverse events or other undesirable side effects; the inherent uncertainty associated with pharmaceutical product development and clinical trials; difficulties or delays in initiating or conducting clinical trials due to difficulties or delays in the regulatory process, enrolling subjects or manufacturing or supplying product for such clinical trials, all of which may be exacerbated by the COVID-19 pandemic; and changes in the competitive landscape for Arcus’s programs. Risks and uncertainties facing Arcus are described more fully in its Annual Report on Form 10-K for the year ended December 31, 2021, filed on February 23, 2022, with the SEC. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Arcus disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release.

The Arcus name and logo are trademarks of Arcus Biosciences, Inc. All other trademarks belong to their respective owners.

Source: Arcus Biosciences


Investor and Media Inquiries:
Holli Kolkey
VP of Corporate Communications
(650) 922-1269

Editor Details

  • Company:
    • Businesswire
Last Updated: 08-Mar-2022